242 related articles for article (PubMed ID: 3310588)
21. Prospective evaluation of a discriminant function for prediction of recurrent symptomatic ventricular tachycardia or ventricular fibrillation in coronary artery disease patients receiving amiodarone and having inducible ventricular tachycardia at electrophysiologic study.
Klein LS; Fineberg N; Heger JJ; Miles WM; Kammerling JM; Chang MS; Zipes DP; Prystowsky EN
Am J Cardiol; 1988 May; 61(13):1024-30. PubMed ID: 3364357
[TBL] [Abstract][Full Text] [Related]
22. Induced sustained ventricular tachycardia in nonischemic dilated cardiomyopathy: dependence on clinical presentation and response to antiarrhythmic agents.
Constantin L; Martins JB; Kienzle MG; Brownstein SL; McCue ML; Hopson RC
Pacing Clin Electrophysiol; 1989 May; 12(5):776-83. PubMed ID: 2471163
[TBL] [Abstract][Full Text] [Related]
23. Ethmozine for ventricular premature complexes.
Gear K; Marcus FI; Huang SK; Fenster PE; Appleton C; Moeller V; Renaud G; Serokman R
Am J Cardiol; 1986 Apr; 57(11):947-9. PubMed ID: 2421571
[TBL] [Abstract][Full Text] [Related]
24. Utility of the signal-averaged electrocardiogram in patients presenting with sustained ventricular tachycardia or fibrillation while on an antiarrhythmic drug.
Nalos PC; Gang ES; Mandel WJ; Myers MR; Oseran DS; Lass Y; Peter T
Am Heart J; 1988 Jan; 115(1 Pt 1):108-14. PubMed ID: 3336965
[TBL] [Abstract][Full Text] [Related]
25. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
26. Effects of Ethmozine (moricizine HCl) on ventricular function using echocardiographic, hemodynamic and radionuclide assessments.
Pratt CM; Podrid PJ; Seals AA; Young JB; Hession M; Lampert S; Quiñones M; Lown B
Am J Cardiol; 1987 Oct; 60(11):73F-78F. PubMed ID: 3310589
[TBL] [Abstract][Full Text] [Related]
27. Effects of sotalol on ventricular tachycardia and fibrillation produced by programmed electrical stimulation: comparison with other antiarrhythmic agents.
Nademanee K; Singh BN
Am J Cardiol; 1990 Jan; 65(2):53A-57A; discussion 65A-66A. PubMed ID: 2403735
[TBL] [Abstract][Full Text] [Related]
28. Effect of moricizine hydrochloride in reducing chronic high-frequency ventricular arrhythmia: results of a prospective, controlled trial.
Singh SN; DiBianco R; Gottdiener JS; Ginsberg R; Fletcher RD
Am J Cardiol; 1984 Mar; 53(6):745-50. PubMed ID: 6367416
[TBL] [Abstract][Full Text] [Related]
29. Clinical electrophysiology, efficacy and safety of chronic oral cibenzoline therapy in refractory ventricular tachycardia.
Rothbart ST; Saksena S
Am J Cardiol; 1986 Apr; 57(11):941-6. PubMed ID: 3515898
[TBL] [Abstract][Full Text] [Related]
30. Efficacy and risks of moricizine in inducible sustained ventricular tachycardia.
Damle R; Levine J; Matos J; Greenberg S; Brooks R; Frumkin W; Goldberger J; Kadish AH
Ann Intern Med; 1992 Mar; 116(5):375-81. PubMed ID: 1736770
[TBL] [Abstract][Full Text] [Related]
31. Reproducibility of programmed electrical stimulation responses in patients with ventricular tachycardia or fibrillation associated with coronary artery disease.
Volgman AS; Zheutlin TA; Mattioni TA; Parker MA; Kehoe RF
Am J Cardiol; 1992 Sep; 70(7):758-63. PubMed ID: 1519526
[TBL] [Abstract][Full Text] [Related]
32. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia.
Connolly SJ; Kates RE; Lebsack CS; Echt DS; Mason JW; Winkle RA
Am J Cardiol; 1983 Dec; 52(10):1208-13. PubMed ID: 6359849
[TBL] [Abstract][Full Text] [Related]
33. Reappraisal of criteria for assessing drug efficacy in patients with ventricular tachyarrhythmias: complete versus partial suppression of inducible arrhythmias.
Borggrefe M; Trampisch HJ; Breithardt G
J Am Coll Cardiol; 1988 Jul; 12(1):140-9. PubMed ID: 3379199
[TBL] [Abstract][Full Text] [Related]
34. [Electrophysiological anti-arrhythmia effects of tiracizine in ventricular tachycardia].
Volkmann H; Kühnert H; Dannberg G; Heinke M; Leeder U; Popp U
Z Gesamte Inn Med; 1991 Dec; 46(17):635-41. PubMed ID: 1776306
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of nadolol alone or in combination with a type IA antiarrhythmic drug in sustained ventricular tachycardia: a prospective study.
Munsif AN; Saksena S
Pacing Clin Electrophysiol; 1989 Nov; 12(11):1816-26. PubMed ID: 2478982
[TBL] [Abstract][Full Text] [Related]
36. The natural history of benign and potentially malignant ventricular arrhythmias with special reference to nonsustained ventricular tachycardia.
Pratt CM; Francis M; Mahler S; Aogaichi K; Keus P; Young JB
Am Heart J; 1988 Oct; 116(4):897-903. PubMed ID: 2459950
[TBL] [Abstract][Full Text] [Related]
37. Efficacy of combination therapy with mexiletine and a type IA agent for inducible ventricular tachyarrhythmias secondary to coronary artery disease.
Greenspan AM; Spielman SR; Webb CR; Sokoloff NM; Rae AP; Horowitz LN
Am J Cardiol; 1985 Aug; 56(4):277-84. PubMed ID: 4025166
[TBL] [Abstract][Full Text] [Related]
38. Cardiac electrophysiologic effects of moricizine hydrochloride.
Bigger JT
Am J Cardiol; 1990 Feb; 65(8):15D-20D; discussion 68D-71D. PubMed ID: 2407089
[TBL] [Abstract][Full Text] [Related]
39. Value of electrophysiologic testing in patients with previous myocardial infarction and nonsustained ventricular tachycardia. Philadelphia Arrhythmia Group.
Kowey PR; Waxman HL; Greenspon A; Greenberg R; Poll D; Kutalek S; Gessman L; Muenz L
Am J Cardiol; 1990 Mar; 65(9):594-8. PubMed ID: 2309629
[TBL] [Abstract][Full Text] [Related]
40. Electrophysiologic assessment of antiarrhythmic drug efficacy for ventricular tachyarrhythmias associated with dilated cardiomyopathy.
Rae AP; Spielman SR; Kutalek SP; Kay HR; Horowitz LN
Am J Cardiol; 1987 Feb; 59(4):291-5. PubMed ID: 3544793
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
